Antibody acquisition and maintenance in childlen with COVID-19: Prospective observational study

Antibody acquisition and maintenance in childlen with COVID-19: Prospective observational study - Pediatric COVID-19 Antibody Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041769

Enrollment

100

Registered

2020-10-01

Start date

2020-10-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2 infection (COVID-19)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria are eligible. (1) Patients who are under 16 years old at the time of registration. (2) Patients residing in Japan. (3) Patients with previous COVID-19 infection confirmed by the PCR or Lamp testing of pharyngeal swab, nasopharyngeal swab, or saliva. (4) Patients who have given their written informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: Patients who meet the following criteria are excluded. (1) Patients with mental illness or other conditions that might affect their ability to consent (2) Patients who are deemed by the researcher to be unsuitable to participate in the research.

Design outcomes

Primary

Measure	Time frame
NP antibody titers at 14 (10 - 18) and 26 (20 - 32) and 52 (46 - 58) weeks after the date of the first positive PCR or other test for COVID-19 infection	—

Secondary

Measure	Time frame
(1) Correlation between neutralizing activity and NP antibody titers at 14, 26 and 52 weeks after the first positive PCR. (2) Correlation between neutralizing activity and NP antibody titer by severity of disease. (3) Distribution of NP antibodies (quantitative and qualitative), SP antibodies (quantitative), neutralizing activity, cytokine, inflammatory markers (FABP, CRP and so on) and autoantibody by sex and age group. (4) Correlation between neutralizing activity and SP antibody titers. (5) Association of baseline background factors, treatment status and severity of disease with neutralizing activity values. (6) Association of baseline background factors, treatment status, and severity of disease with NP antibody titers. (7)Six types of antibody titer and neutralizing activity against human coronavirus. (8)Cytokines, inflammatory markers and autoantibody. (9)Neutralization activity value and antibody titer against SARS-CoV-2 and correlation of virus antibody titer and neutralizing activity against 6 human coronaviruses .	—

Measure

Time frame

(1) Correlation between neutralizing activity and NP antibody titers at 14, 26 and 52 weeks after the first positive PCR. (2) Correlation between neutralizing activity and NP antibody titer by severity of disease. (3) Distribution of NP antibodies (quantitative and qualitative), SP antibodies (quantitative), neutralizing activity, cytokine, inflammatory markers (FABP, CRP and so on) and autoantibody by sex and age group. (4) Correlation between neutralizing activity and SP antibody titers. (5) Association of baseline background factors, treatment status and severity of disease with neutralizing activity values. (6) Association of baseline background factors, treatment status, and severity of disease with NP antibody titers. (7)Six types of antibody titer and neutralizing activity against human coronavirus. (8)Cytokines, inflammatory markers and autoantibody. (9)Neutralization activity value and antibody titer against SARS-CoV-2 and correlation of virus antibody titer and neutralizing activity against 6 human coronaviruses .

—

Countries

Japan

Contacts

Public ContactKenichi Nishimura

Yokohama City University Hospital Department of Pediatrics

k_nsm@yokohama-cu.ac.jp045-787-2800

Outcome results